Under the trend of innovation, the pharmaceutical industry has set off a wave of cooperation

Recently, reports have shown that Beihai Kangcheng, which has been committed to the research, development and commercialization of innovative therapies, announced that it has signed a research cooperation and licensing agreement with scriptr Global to cooperate in the development of gene therapy products against dystrophin disease
.
The agreement shows that after the cooperation, Beihai Kangcheng will have the exclusive global authorization of scriptr Global to develop, produce and commercialize dystrophin by using the company’s Stitchr™ platform (a proprietary ribozyme-mediated RNA assembly technology) Candidates for gene therapy of diseases
.
At that time, scriptr Global will be responsible for technical research, while Beihai Kangcheng will assume all responsibilities for product development, production, registration and commercialization
.
On October 22, Genetron Health, which focuses on providing tumor molecular detection, cancer early screening and companion diagnostic development services, announced that it has entered into an agreement with Jiangsu Fosun Pharmaceutical Sales Co.
, Ltd.
("Jiangsu Fosun Pharmaceutical"), a subsidiary of Fosun Pharmaceutical Holdings.
Genetron Health Seq-MRD® (hematological tumor minimal residual disease) testing services signed an exclusive commercialization cooperation agreement
.
Data show that Seq-MRD® is a molecular diagnostic method for detecting and monitoring minimal residual disease in specific hematological tumors
.
According to the agreement, Genetron Health and Jiangsu Fosun Pharma will jointly sell and jointly promote Seq-MRD® in key hospitals and clinics for hematological diseases in designated areas in China to serve acute lymphoblastic leukemia, multiple myeloma, chronic lymphocytic leukemia, etc.
Patients with lymphatic blood tumors
.
On October 15, Hansen Pharmaceutical also issued an announcement stating that it has entered into an exclusive license cooperation agreement with Silence Therapeutics plc
.
According to the announcement, Hansen Pharmaceuticals and Silence Therapeutics will use Silence Therpaeutics' exclusive mRNAi GOLD™ platform to jointly develop siRNA (short interfering RNA) targeting three targets
.
It is worth mentioning that on the 12th, Hansen Pharmaceuticals also entered into an exclusive license cooperation agreement ("License Agreement") with OliX Pharmaceuticals, Inc.
, OliX Pharmaceuticals will use GalNAc-asiRNA platform technology to discover lead drugs and ensure that they are targeted at the liver Development of drug candidates for related cardiovascular, metabolic and other disease targets
.
In addition to the above companies, in fact, this year, a large number of pharmaceutical companies have also announced that they have invested heavily in the development and sales of innovative drugs and therapies in cooperation with other companies
.
In this regard, the industry believes that this is a manifestation of pharmaceutical companies' continuous betting on innovative drugs in order to balance policies and the market
.
In recent years, China's innovative drug industry has been booming, and the emerging biotech companies (biotech) have begun to focus on innovation
.
At the same time, traditional large pharmaceutical companies (big pharma) are also actively transforming and innovating
.
But innovation is not a simple matter.
It often requires a lot of capital investment, time and energy.
Therefore, cooperative development has become the choice of many companies
.
The industry believes that under the influence of the current environment, the situation of unilateral advancement of local innovative drug companies in the future will be further changed, and the relationship between more and more pharmaceutical companies will change from competition to "competition + cooperation"
.
, Enterprises with strong R&D capabilities, especially focusing on R&D in a certain disease field, as well as with drug declaration capabilities and excellent drug commercialization capabilities, may usher in more development opportunities in the future under the general trend of industry innovation
.